No Cover Image

Journal article 685 views 1176 downloads

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Michele Maio, Patrick Schöffski, Matteo S. Carlino, Céleste Lebbé, Grant McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Lars Bastholt, Jasmine I. Rizzo, Agnes Balogh, Andriy Moshyk, Massimo Guidoboni, John Haanen, Andrew Hill, F. Stephen Hodi, David Hogg, Michael Smylie, Pier F. Ferrucci, Reinhard Dummer, John Wagstaff, Dirk Schadendorf, C. Lance Cowey, Christopher D. Lao, Piotr Rutkowski, Jean-Jacques Grob, Rene Gonzalez, Vanna Chiarion-Sileni, James Larkin, Ivan Márquez-Rodas, Jedd D. Wolchok

New England Journal of Medicine, Volume: 381, Issue: 16, Pages: 1535 - 1546

Swansea University Author: John Wagstaff

  • 52612.pdf

    PDF | Version of Record

    Copyright © (2019) Massachusetts Medical Society. Reprinted with permission

    Download (345.88KB)

Check full text

DOI (Published version): 10.1056/nejmoa1910836

Abstract

945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipili...

Full description

Published in: New England Journal of Medicine
ISSN: 0028-4793 1533-4406
Published: Massachusetts Medical Society 2019
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa52612
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: 945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipilimumab/nivo, 45% of nivo and 19% of Ipilimumab patients. Complete responses were seen in 22% (Ipilimumab/nivo), 19% (nivo) and 6% (Ipi) patients. Overall survival (OS) at five years was 52% (Ipilimumab/nivo), 44% (nivo) and 26% (Ipi). In patients with and without bras mutations the OS at five years was 60 & 48% (Ipilimumab/nivo), 46 & 43% (nivo) and 30 & 25% (Ipi) respectively. OS curves were flat beyond three years indicating that these treatments lead to sustained long term survival of these patients.
Keywords: Melanoma, ipilimumab, nivolumab, overall survival
College: Faculty of Medicine, Health and Life Sciences
Issue: 16
Start Page: 1535
End Page: 1546

Similar Items